Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

361
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
361
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

684
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
684
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

251
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
251
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

30
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
30
Neural Regulation01:37

Neural Regulation

39.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.7K
Cancer Prevention02:59

Cancer Prevention

6.3K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.3K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Early Alzheimer´s disease blood biomarkers are associated with a higher risk for postoperative long-term cognitive decline: Insights from the FINDERI study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

A comprehensive assessment of lifecourse and mortality of Parkinson's disease in the German National Cohort.

NPJ Parkinson's disease·2026
Same author

Teleguided Point-of-Care Ultrasound for Fluid Assessment in Geriatric Inpatients Performed by Nurses and Medical Students: Prospective Observational Feasibility Study.

JMIR formative research·2026
Same author

Genetic associations between post-traumatic stress disorder and REM-sleep behavior disorder.

NPJ Parkinson's disease·2026
Same author

A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism.

Nature medicine·2026
Same author

Multi-locus genetic dosage shapes cognitive disease progression in Parkinson's patients: 15-year meta-analysis of 24 cohorts.

NPJ Parkinson's disease·2026

関連する実験動画

Updated: Sep 1, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K

パーキンソン病を予防する

Brit Mollenhauer1, Christine A F von Arnim2

  • 1Department of Neurology, University Medical Center Göttingen and Paracelsus-Elena-Klinik, Kassel, Germany.

Science (New York, N.Y.)
|August 18, 2022
PubMed
まとめ

特定のグリコタンパク質は,パーキンソン病の進行を早期に示す指標として機能する. この発見は神経変性疾患の よりよいモニタリングにつながります

科学分野:

  • 神経生物学
  • バイオマーカーの発見

背景:

  • パーキンソン病は進行性神経変性疾患です
  • 病気の進行に対する信頼性の高いバイオマーカーを特定することは 効果的な管理に不可欠です

研究 の 目的:

  • パーキンソン病の病原性進行のバイオマーカーとしての特定のグリコタンパク質の可能性を調査する.

主な方法:

  • 関連する生物学的サンプルにおけるグリコタンパク質濃度の分析
  • 糖タンパク質濃度と疾患の重症度および進行マーカーの相関

主要な成果:

  • パーキンソン病の進行の潜在的指標として特定された.

結論:

  • このグリコプロテインは パーキンソン病をモニタリングする バイオマーカーとして有望です
  • 臨床的有用性を検証するためにさらなる研究が必要である.

さらに関連する動画

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
04:08

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

Published on: January 18, 2021

2.9K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

18.1K

関連する実験動画

Last Updated: Sep 1, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K
Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
04:08

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

Published on: January 18, 2021

2.9K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

18.1K